No difference in clinical progression between patients infected with the predominant human immunodeficiency virus type 1 circulating recombinant form (CRF) 02_AG strain and patients not infected with CRF02_AG, in Western and West-Central Africa: a f
about
Functional characteristics of HIV-1 subtype C compatible with increased heterosexual transmissibility.Lack of adaptation to human tetherin in HIV-1 group O and P.The impact of monitoring HIV patients prior to treatment in resource-poor settings: insights from mathematical modellingImpact of HIV-1 viral subtype on disease progression and response to antiretroviral therapy.Examining the promise of HIV elimination by 'test and treat' in hyperendemic settings.Development and validation of decision rules to guide frequency of monitoring CD4 cell count in HIV-1 infection before starting antiretroviral therapyIdentification and genetic characterization of a novel CRF22_01A1 recombinant form of HIV type 1 in Cameroon.HIV-1 subtype distribution in the Gambia and the significant presence of CRF49_cpx, a novel circulating recombinant form.COMET: adaptive context-based modeling for ultrafast HIV-1 subtype identification.The predominance of Human Immunodeficiency Virus type 1 (HIV-1) circulating recombinant form 02 (CRF02_AG) in West Central Africa may be related to its replicative fitness.Mechanisms and factors that influence high frequency retroviral recombinationPrevalence of human immunodeficiency virus drug resistance mutations and subtypes in drug-naive, infected individuals in the army health service of Rio de Janeiro, Brazil.New indicators for delay in initiation of antiretroviral treatment: estimates for CameroonThe challenge of HIV-1 subtype diversity.Estimating the resources required in the roll-out of universal access to antiretroviral treatment in Zimbabwe.Disease progression by infecting HIV-1 subtype in a seroconverter cohort in sub-Saharan Africa.Molecular epidemiology of human immunodeficiency virus type 1 sub-subtype A3 in Senegal from 1988 to 2001.Sub-Saharan African migrants living with HIV acquired after migration, France, ANRS PARCOURS study, 2012 to 2013.Biological signature characteristics of primary isolates from human immunodeficiency virus type 1 group O in ex vivo human tonsil histocultures.Faster progression to AIDS and AIDS-related death among seroincident individuals infected with recombinant HIV-1 A3/CRF02_AG compared with sub-subtype A3.Virological response, HIV-1 drug resistance mutations and genetic diversity among patients on first-line antiretroviral therapy in N'Djamena, Chad: findings from a cross-sectional study.High plasma HIV load in the CRF01-AE outbreak among injecting drug users in Finland.Impact of HIV-1 Subtype on CD4 Count at HIV Seroconversion, Rate of Decline, and Viral Load Set Point in European Seroconverter Cohorts
P2860
Q30376421-D08D2721-B5EB-46AF-8213-3067AE8AC7EEQ30407564-6AB6AD1A-A7E8-48DD-BA80-C157DFCA7184Q33323442-499DF6E1-1D9C-4D65-9E65-D6A7BBB0617EQ33683115-FAA808A2-8AE8-473E-B408-753752385BDCQ33780939-34BDBF65-A958-4933-8BDF-4222DD7AA44EQ33873614-EF4E7CDB-951A-44EB-90E6-D78E9C34D4A0Q34098161-95AF77B7-331C-4E73-A44D-A0102E316A66Q34243456-A2CAFA86-FD7A-46AB-8796-5928E92C695CQ34312943-F282311C-48E8-4D2E-8728-C57CC24C188BQ34885559-F157F978-D3A5-4A8F-A85B-2CBB9994F987Q35276750-57AFB713-528F-420A-933F-178F5724B6DEQ35551677-2D8F4F5E-2EEF-44FD-95A8-A2F7DF24D0D9Q36089497-DCE54A44-4521-4BF4-97F2-BAB29B702744Q37038453-6070A890-2992-4530-B811-AEDA66B74C60Q37063081-9CC79727-4629-47CC-907D-4AF9350A248EQ37273037-DC4E9367-7C12-4960-BEB9-0D38195A77A3Q37596583-F946EB6A-485A-4ED1-BD83-9910842D13BCQ38970967-EDF260EF-F66C-4D5F-B30A-E766740E3CD5Q39808350-849A5F7E-B4F8-430C-AE4B-853307EEC27EQ42277493-E45D5563-E5AB-4FCA-BA8D-96134FF8FCD5Q46331291-CB1EF3B8-DDF8-4B13-A5EA-8DDE569D2886Q53677529-147DF3E5-97B1-4E26-AA24-19D74086476EQ57708705-3D02244F-66C9-4200-B327-E7F31CAE6069
P2860
No difference in clinical progression between patients infected with the predominant human immunodeficiency virus type 1 circulating recombinant form (CRF) 02_AG strain and patients not infected with CRF02_AG, in Western and West-Central Africa: a f
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
No difference in clinical prog ...... n and West-Central Africa: a f
@en
No difference in clinical prog ...... n and West-Central Africa: a f
@nl
type
label
No difference in clinical prog ...... n and West-Central Africa: a f
@en
No difference in clinical prog ...... n and West-Central Africa: a f
@nl
prefLabel
No difference in clinical prog ...... n and West-Central Africa: a f
@en
No difference in clinical prog ...... n and West-Central Africa: a f
@nl
P2093
P50
P356
P1476
No difference in clinical prog ...... n and West-Central Africa: a f
@en
P2093
Anke Bourgeois
Christelle Butel
Christian Laurent
Coumba Touré Kane
Josephine Mbuagbaw
Léopold Zekeng
Mame Awa Faye
Mandoumbé Gueye
Moussa Seydi
Rose Mougnutou
P304
P356
10.1086/341833
P407
P577
2002-07-19T00:00:00Z